leverage ai to predict the success of trial product launches ✌️【365vc.net】✌️Start investing with just ₹500. Leverage AI tools for smart decisions and maximize your profits. Join now! leverage ai to predict the success of trial product launches - Low Risk High Rewards Simplified Wealth Management with Great Results
leverage ai to predict the success of trial product launches ✌️【365vc.net】✌️Start investing with just ₹500. Leverage AI tools for smart decisions and maximize your profits. Join now!Serum Institute of India (SII) has entered into an exclusive licence agreement with French speciality vaccine company Valneva SE to manufacture and sell Valneva’s chikungunya vaccine in India and the rest of Asia.Valneva’s chikungunya vaccine is the world’s first and only licensed vaccine.
It is currently approved in the US, Europe, and Canada for adults. Regulatory reviews are underway to expand it to children up to 12 years.Chikungunya virus is a mosquito-borne viral disease spread by the bites of infected Aedes mosquitoes.
It causes fever, severe joint and muscle pain, headache, nausea, fatigue, and rash.
leverage ai to predict the success of trial product launches ✌️【365vc.net】✌️₹500 investment to unlock massive monthly income. Start now and grow your earnings online!The joint pain is often debilitating and can persist for weeks to years.Indiais currently enduring one of its worst chikungunya outbreaks.
Nearly 3,70,000 cases were confirmed in India between January 2019 and July 2024, and it was rapidly increasing due to the current outbreak.
leverage ai to predict the success of trial product launches ✌️【365vc.net】✌️Start investing with just ₹500. Leverage AI tools for smart decisions and maximize your profits. Join now!Both companies will work to bring the vaccine to the Indianmarketand some Asian countries, after approval from local regulators.SII has committed to a priority supply of the chikungunya vaccine at an affordable price to publichealthmarkets in low- and middle-income countries (LMICs).leverage ai to predict the success of trial product launches Start Investing with ₹500, Earn 100% Monthly Returns
